期刊文献+

磁性纳米微粒介导的尿前列腺癌抗原3检测诊断前列腺癌的价值 被引量:1

Diagnostic accuracy of urinary PCA3 test by magnetic nanoparticle mediated approach for prostate cancer
下载PDF
导出
摘要 目的探讨磁性纳米微粒介导的尿前列腺癌抗原3(PCA3)检测诊断前列腺癌的价值。方法对2014年9月至2015年5月在我院行前列腺穿刺活检的90例患者行诊断试验研究。诊断试验为尿PCA3检测,分别采用磁性纳米微粒介导法和传统尿沉淀法。诊断的金标准为前列腺穿刺活检病理。绘制尿PCA3诊断前列腺癌的受试者工作特征曲线,计算曲线下面积(AUC),比较两种不同检测方法诊断前列腺癌的价值,计算灵敏度和特异度等。结果 90例患者中活检诊断前列腺癌25例,磁性纳米微粒介导法的AUC为0.934(95%CI=0.881~0.986,P〈0.001),高于传统尿沉淀法的0.792(95%CI=0.668~0.915,P〈0.001)。磁性纳米微粒介导法测得的尿PCA3分值,当临界点为25时,诊断前列腺癌的敏感度为77.3%,特异度为91.2%。结论磁性纳米微粒介导的尿PCA3检测,能提高检测的敏感性,诊断价值优于传统尿沉淀法。 Objective To investigate the diagnostic accuracy of urinary prostate cancer antigen 3(PCA3)test by magnetic nanoparticle mediated approach for prostate cancer.Methods Altogether 90 patients who received prostate biopsy in our department during Sept.2014 and May 2015 were enrolled in this prospective study.All patients had indications of prostate biopsy due to elevated prostate specific antigen or abnormal results of digital rectal examination.The index tests were urinary PCA3 tests,either by magnetic nanoparticle mediated approach or urinary sediment approach.The gold standard of diagnosis for prostate cancer was prostate biopsy.The receiver operating characteristic curves of PCA3 were drawn and area under curve(AUC)was calculated to compare the diagnostic accuracy of the two different approaches.Sensitivity,specificity,positive predictive value,negative predictive value and likelihood ratio were calculated.Results Among the 90 cases,25 were diagnosed as prostate cancer.The AUC obtained by the magnetic nanoparticle mediated approach was 0.934(95%CI,0.881~0.986,P0.001),higher than that by the traditional sediment approach,which was 0.792(95%CI,0.668~0.915,P0.001).For nanoparticle mediated approach,when the cutoff value of PCA3 score was 25,the sensitivity was 77.3%,and the specificity was 91.2% for the diagnosis of prostate cancer.Conclusion The diagnostic accuracy of urinary PCA3 test by magnetic nanoparticle mediated approach is superior to that by urinary sediment approach.
出处 《现代泌尿外科杂志》 CAS 2016年第4期256-259,共4页 Journal of Modern Urology
基金 上海市医学重点专科基金(No.ZK2012A22) 上海市科委自然科学基金(No.14ZR1432900) 上海市卫生和计划生育委员会青年科研项目(No.20124y197) 闵行区自然科学研究课题(No.2011MHZ36)
关键词 前列腺癌 诊断试验 前列腺癌抗原3 磁性纳米微粒 尿沉淀 prostate neoplasm diagnostic accuracy test prostate cancer antigen 3 magnetic nanoparticle urinary sediment
  • 相关文献

参考文献14

  • 1WACHTEL MS, NELIUS T, HAYNES AL, et al. screening and deaths from prostate cancer after diagnosis PSA - a populationbased analysis[J~. Prostate, 2013,73(12): 1365 1369.
  • 22009年上海市恶性肿瘤发病率[J].上海预防医学,2013,25(1):54-55. 被引量:10
  • 3BHINDI B, MAMDANI M, KULKARNI GS, et al. Impact of the U. S. preventive services task {orce recommendations against prostate specific antigen screening on prostate biopsy and cancerdetection rates[J]. J Urol,2015,193(5) ..1519-1524.
  • 4LEYTEN GH, HESSELS D, JANNINK SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fu- sions as diagnostic and prognostic urinary biomarkers for pros- tate cancer[J]. Eur Urol,2014,65(3):534-542.
  • 5王伟,何家扬,施国伟.前列腺癌抗原3研究进展[J].中华泌尿外科杂志,2011,32(11):789-791. 被引量:1
  • 6朱国栋,杨志尚,吴大鹏,宋文斌,陈炜,李磊.前列腺癌标志物PCA3的研究进展[J].现代泌尿外科杂志,2014,19(10):698-702. 被引量:7
  • 7KARIMI Z, KARIMI L, SHOKROLLAHI H. Nano-magnetic particles used in biomedicine: core and coating materials['J']. Mater Sci Eng C Mater Biol Appl,2013,33(5): 2465-2475.
  • 8BORLIDO L, AZEVEDO AM, ROQUE AC, et al. Magnetic separations in biotechnologyEJ~. Biotechnol Adv, 2013,31 (8) : 1374-1385.
  • 9TOMLINS SA. Urine PCA3 and TMPRSS2:ERG using cancer- specific markers to detect cancer[J]. Eur Urol, 2014,65 (3) : 543- 545.
  • 10吴义启,刘修恒.前列腺特异性抗原前体2型及其百分比、前列腺健康指数对前列腺癌的诊断价值[J].现代泌尿外科杂志,2015,20(7):525-527. 被引量:10

二级参考文献70

  • 1陈爱萍,孙红,姚莉,蔡虻.持续质量改进在护理质量管理中的应用[J].中华护理杂志,2005,40(2):123-124. 被引量:264
  • 2陈丽芳.急诊科护理质量管理与持续改进的实践[J].护理管理杂志,2006,6(2):23-24. 被引量:52
  • 3Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin, 2008, 58 : 71-96.
  • 4Stamey TA, Johnstone IM, McNeal JE, et al. Preoperative serum prostate speci- fic antigen levels between 2 and 22 ng/ml correlate poorly with post-radical prostatectomy cancer morphology: pros- tate specific antigen cure rates appear constant between 2 and 9 ng/ml. J Urol, 2002, 167: 103-111.
  • 5Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overex- pressed in prostate cancer. Cancer Res,1999,59:5975-5979.
  • 6Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3 ( PCA3 ) -based mo- lecular urine analysis for the diagnosis of prostate cancer. Eur Urol, 2003, 44: 8-15.
  • 7Clarke RA, Zhao Z, Guo AY, et al. New genomic structure for prostate can- cer specific gene PCA3 within BMCC1 : implications for prostate cancer detection and progression. PLoS One, 2009, d: e4995.
  • 8Salagierski M, Verhaegh GW, Jannink SA, et al. Differential expression of PCA3 and its overlapping PRUNE2 transcript in prostate cancer. Prostate, 2010, 70: 70-78.
  • 9Szell M, Bata-Csorgo Z, Kemeny L. The enigmatic world of mRNA-like ncRNAs: their role in human evolution and in hu- man diseases. Semin Cancer Biol, 2008, 18:141-148.
  • 10Day JR, Jost M, Reynolds MA, et al. PCA3: from basic molecular science to the clinical lab. Cancer Lett, 2011, 301 : 1-6.

共引文献24

同被引文献6

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部